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Summary During recent years N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers have been
developed as targetable drug carriers. These soluble synthetic polymers are internalized by cells by pinocytosis
and they can be tailor-made to include peptidyl side-chains degradable intracellularly by specific lysosomal
enzymes. Thus they provide the opportunity fo achieve controlled intracellular delivery of anticancer agents.
The anthracycline antibiotic daunomycin, and protein synthesis inhibitor puromycin, were bound to HPMA
copolymers via several different peptide side-chains, including Gly-Gly, Gly-Phe-Leu-Gly and Gly-Phe-Phe-
Leu. Incubation of polymer-drug conjugates with isolated lysosomal enzymes (either a mixture of rat liver
lysosomal enzymes or purified thiol-dependent lysosomal proteinases, cathepsins L and B) showed that
significant release of drug occurred over 20h, more than 20% of daunomycin and more than 80% of
puromycin being liberated. To test their pharmacological activity conjugates were incubated with either the
mouse leukaemia L1210, or the human lymphoblastoid leukaemia CCRF in vitro. The conjugates tested were
all less effective than free daunomycin, but they showed differential toxicity against L1210 depending on the
aminoacid sequence of their drug-polymer linkage. Inclusion of fucosylamine-terminating side-chains into the
HPMA copolymer structure increased the affinity of conjugates for the L1210 cell membrane and resulted in
increased toxicity. In contrast HPMA-daunomycin conjugates with or without fucosylamine affected CCRF
cells equally, but this cell line was more sensitive than the mouse leukaemia to both free and polymer-bound
daunomycin. Incubation of L1210 cells in polymer-bound daunomycin for 72h, followed by plating cells out
in low density in drug-free medium, showed that a concentration of polymer-bound drug (184,ugml-1) could
be selected to achieve a cytotoxic effect.
The need to achieve drug targeting in cancer chemotherapy
has long been realized (for reviews see Zaharko et al., 1979;
Gregoriadis, 1981). Use of liposomes and microparticles to
achieve this goal has proved largely unsuccessful owing to
the difficulty they have in gaining access to most tumours
and to their avid phagocytic capture by the reticuloendo-
thelial system (Poste, 1983; Kato, 1983). Soluble macro-
molecular drug carriers seem to offer greater potential as
they can traverse compartmental barriers in the body
(Cartlidge et al., 1986) and therefore gain access to a greater
number of cell types, and in most cases are not subject to
rapid clearance by the reticuloendothelial cells (Duncan et
al., 1986; Seymour et al., 1986). Natural macromolecules
such as dextran (Arnon, 1982), human serum albumin
(Trouet et al., 1980) and tumour-specific antibodies (Garnett
et al., 1985) have all been evaluated as carriers of antitumour
agents. Each system has advantages in terms of tumour
specificity or ease of chemical conjugation, but each also
poses problems of limited body distribution and/or
immunogenicity.
N-(2-Hydroxypropyl)methacrylamide (HPMA) homo-
polymers were originally developed as plasma expanders
(Kopecek et al., 1973) and more recently HPMA copolymers
have undergone considerable development as a targetable
drug delivery system (Kopecek & Duncan, 1986). These
copolymers can be tailor-made to include oligopeptide drug-
polymer linkages that are stable in the circulation
(Rejmanova et al., 1985), but readily degraded intracellularly
by the lysosomal thiol-dependent (cysteine-) proteinases
(Duncan et al., 1983; Rejmanova et al., 1983). HPMA
copolymers can also be synthesized to include potentially
useful targeting residues, such as galactose, which target the
polymer efficiently to hepatocytes (Duncan et al., 1983a;
Duncan et al., 1986) or immunoglobulins (rat IgG) (Duncan
et al., 1985) and anti 0 antibodies (1iAhovai & Kopecek, 1986;
Iklhova' et al., 1986).
This study represents the first evaluation of pharmaco-
logical activity of antitumour drugs (daunomycin and puro-
mycin) conjugated to HPMA copolymers. It has been found
previously that the rate of enzymic release of terminal
groups from the oligopeptide side-chains of HPMA
copolymers depends on the nature of the terminal moiety
(Kopecek, 1984). This makes any simple extrapolation from
data obtained with model compounds, such as p-nitroaniline
(Duncan et al., 1983) to the situation encountered with
real drugs somewhat difficult. To establish the rates of
degradation of HPMA side-chain, sequences terminating in
daunomycin or puromycin were incubated with either a
mixture of lysosomal enzymes (tritosomes (Trouet, 1974)) or
with purified cysteine-proteinases (cathepsins B and L).
To investigate the cytotoxicity of HPMA copolymer-drug
conjugates, the mouse leukaemia L1210 was chosen as the
primary in vitro screen. This technique has been routinely
used as one of the primary test systems by the National
Cancer Institute (Geran et al., 1972) and permits parallel in
vivo experiments to be undertaken in DBA2 mice. Also, the
L1210 leukaemia is known to carry a membrane receptor
that recognizes fucose residues on macromolecular ligands
(Monsigny et al., 1984) and this permits attempts at
targeting using polymers bearing both fucosylamine and
drug. To monitor drug-conjugate activity against a human
cell line, CCRF lymphoblastoid leukaemia was selected. The
in vitro experiments carried out in this study took one of two
forms. First, cells were incubated continuously with various
concentrations of free drug or polymer-bound drug for 72 h.
The suspension cultures were counted, using a Coulter
Counter, before and after this period and the effect of drugs
on growth assessed. Secondly, in certain experiments, the
cells were washed free of drug-conjugate and plated out at
low density. Any cetl growth over the following ten days was
monitored.
To examine the binding and rate of pinocytic internal-
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ization of HPMA conjugates by cells, selected polymers were
radioiodinated and incubated with L1210 cells for period up
to 24h. The effect of low temperature on accumulation of
radioactivity was also examined in an attempt to elucidate
the mechanism of polymer-cell interaction.
Materials and methods
Chemicals
1-Aminopropan-2-ol, methacryloylchloride, glycylglycine, di-
methylsulphoxide (DMSO) and 4-nitrophenol were from
Fluka AG, Buchs, Switzerland. Glycylphenylalanine, leucyl-
glycine, phenylalanylleucine, 2,4-dinitrophenol, tyrosinamide,
galactosamine, fucosylamine and puromycin were from Sigma
Chemical Co., Poole, Dorset, UK. Daunomycin (DNM) was
kindly donated by Rhone-Poulenc, Paris, France. Leupeptin
was from the Peptide Institute, Osaka, Japan. [125I]Iodide
(preparation IMS.30) was from Amersham International,
UK.
Monomers
Monomers were prepared as previously described: N-(2-
hydroxypropyl)methacrylamide (Strohalm & Kopecek, 1978).
N-methacryloylglycylglycinep-nitrophenyl ester(MA-Gly-Gly-
ONp) (Rejmanova et al., 1977), N-methacryloylglycyl-
ohenylalanylleucylglycine p-nitrophenyl ester (MA-Gly-Phe-
Leu-Gly-ONp) (Kopecek et al., 1985a), N-methacryloyltyro-
sinamide (Duncan et al., 1984).
Cell culture
L1210 cells, CCRF cells and foetal bovine serum were from
Flow Labs., Rickmansworth, Herts., UK. Tissue culture
medium RPMI and heat inactivated horse serum were from
Gibco Ltd., Paisley, Scotland, UK.
Preparation ofN-(2-hydroxypropyl)methacrylamide
copolymers
Polymer-drug conjugates were synthesized using a two-stage
procedure. In the first step the polymer precursors shown in
Table I were synthesized by radical precipitation copolymer-
isation (Kopecek, 1977; Kopecek & Rejmanova, 1979) of
HPMA, MA-Tyr-NH2 and the respective N-methacryloyl-
oligopeptide p-nitrophenyl ester (scheme given in Figure 1).
The polymer precursors were isolated and characterized by
measuring their molecular weight distribution and content of
side chains.
In the second step, drugs (daunomycin, puromycin) and in
some cases targeting moieties (galactosamine, fucosylamine)
were bound to these polymer precursors by consecutive
aminolysis (Kopecek et al., 1985) as shown in Figure 1, to
give the polymers listed in Table II. During consecutive
aminolysis minimal changes in molecular weight distribution
were observed.
Synthesis of copolymer 11, i.e. binding of daunomycin and
galactosamine to polymer precursor 4 is described in detail
as a typical example. Polymer precursor 4 (210 mg, containing
9.5 x 10-5mol of ONp groups) was dissolved in DMSO
(0.8ml). Daunomycin hydrochloride in 0.2ml DMSO (35 mg,
6.2 x 10-5mol) and triethylamine (6.3 mg, 6.2 x 10-5mol)
were then added whilst stirring continuously. The reaction
was allowed to continue for 1.5 h in the dark, at room
temperature. Then galactosamine hydrochloride (36.6mg,
1.4x 10-4mol) and triethylamine (14.4mg, 1.4x 10-4mol)
were added. The reaction mixture was then stirred for 16h
in the dark, at room temperature. Aminopropan-2-ol (10pg)
was added at the end of this time to inactivate any remaining
ONp groups. After 5min the polymer was isolated by
precipitation into a mixture of 400ml acetone and 100ml
diethyl ether. The polymer was isolated by filtration, dis-
solved in methanol (1.3ml) and reprecipitated into a mixture
of 200ml acetone and 50ml of diethyl ether (yield 185mg).
The polymer obtained contained some unbound DNM. To
remove the latter, the polymer was dissolved in methanol
and purified by gel filtration on Sephadex LH-20 (column
.2 x 95 cm, eluent methanol). The high molecular weight
fraction was isolated and methanol evaporated. (Dialysis or
ultrafiltration were both found to be inefficient at removing
unbound DNM).
The polymer was subsequently dissolved in water and
freeze-dried (yield 170mg). The product contained a 3.5mol%
of side-chains terminating in DNM (10.2wt% of drug) and
2.0mol% of side-chains terminating in galactosamine
Table I Characteristics of polymer precursors
Content of
Polymer side-chains
code no. Structurea (mol%) Mb MW/Mn
Tyr-NH2 1.0
/
1 P
Gly-Gly-ONp 4.0 21,000 1.3
Tyr-NH2 1.0
/
2 P
Gly-Phe-Phe-Leu-ONp 3.0 31,000 1.4
Tyr-NH2 1.0
/
3 P
Gly-Phe-Leu-Gly-ONp 4.7 28,000 1.3
Tyr-NH2 1.0
4 P
Gly-Phe-Leu-Gly-ONp 8.0 17,000 1.3
ap...polymer backbone; "The Mw and M. of the copolymers was estimated
after their aminolysis with 1-aminopropan-2-ol by GPC analysis on Sepharose
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First step: copolymerization
50°C; acetone
HPMA + MA-Gly-Phe-Leu-Gly-ONp + MA-Tyr-NH2
azobisisobutyronitrile
Tyr-NH2
p
Gly-Phe-Leu-Gly-ONp-
polymer precursor 4
Second step: consecutive aminolysis
Tyr-NH2
P GlIy-Phe-Leu-GlIy-ONp
1. DNM
2. galactosamine
Do
DMSO; room temp.
Tyr-NH2
P Gly-Phe-Leu-Gly-DNM
Gly-Phe-Leu-Gly-DNM
copolymer 1 1
Chemical structure of Copolymer 11:
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Figure 1 Structure of HPMA copolymer-drug conjugates.
(2.0wt%). The amount of bound DNM was determined
spectrophotometrically using c480=9.8xIO31mol-1cm-1 in
H20. Unbound DNM was determined by extracting into ethyl
acetate. Copolymer (min1.5mg) was dissolved in ml H20
and extracted (shaken) with a mixture of ml buffer
(0.2M Na2CO3/NaHCO3, pH9.8) and 2ml of ethyl acetate.
The organic layer was separated, dried with a small amount
of dry MgSO4. The concentration of DNM was determined
spectrophotometrically (6480 = 1.0 x 104 in ethylacetate). The
polymer contained less than 0.1 relative % of DNM, as
compared to the amount of bound DNM. Galatosamine
content of polymers was estimated as previously described
(Plummer et al., 1976; Cheng & Boat, 1978). Copolymers were
hydrolysed in sealed evacuated tubes using 4N HCl,
maintained at 100°C for 4h. The sugar content was
determined using an amino acid analyser.
Fucosylamine content was estimated from kinetic measure-
ments of the reaction between the polymeric precursor and
fucosylamine using u.v. photospectroscopy (decrease in
absorbance of leaving p-nitrophenyl ester groups).
Copolymers containing puromycin and galactosamine (i.e.
copolymer 8) was prepared similarly, with the exception that
free puromycin was removed from the polymer-drug conju-
gate by dialysis in Visking tubing (methanol (10% in water),
H20). The amount of bound puromycin was determined
spectrophotometrically using 272 2.0 x 104 mol- 1 cm-1
and the puromycin-containing polymers also contained less
than 0.1 relative % of free drug.
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Table II Characteristics of polymer-drug conjugates
Synthesis
Content of
Polymer side-chains Precursor no.
code no. Structurea (mol%) (See Table I) Aminolysed by
Tyr-NH, 1.0 1 DNM
5 P
Gly-Gly-DNM 3.1
Tyr-NH2
6 P
Gly-Phe-Phe-Leu-DNM
Tyr-NH2
7 P-Gly-Phe-Phe-Leu-PRM
Gly-Phe-Phe-Leu-galactosamine
1.0 2 DNM
2.2
1.0
1.3
0.9
2 a/PRM
b/galactosamine
Tyr-NH2
8 P
Gly-Phe-Leu-Gly-DNM
1.0 3 DNM
3.0
1.0 Tyr-NH2
9 P
3 PRM
Gly-Phe-Leu-Gly-PRM
Tyr-NH2
10 P-Gly-Phe-Leu-Gly-PRM
GIy-Phe-Leu-Gly-galactosamine
Tyr-NH2
11 P-Gly-Phe-Leu-Gly-DNM
Gly-Phe-Leu-Gly-galactosamine
Tyr-NH2
12 P-Gly-Phe-Leu-Gly-DNM
1.0
2.3
1.8
1.0
3.5
2.0
1.0
2.2
3 a/PRM
b/galactosamine
4 a/DNM
b/galactosamine
4 a/DNM
b/fucosylamine
Gly-Phe-Leu-Gly-fucosylamine
aDNM: daunomycin, PRM: puromycin.
Cleavage ofHPMA copolymer-drug conjugates by lysosomal
enzymes in vitro
Enzymes
Two sources of lysosomal enzymes were used: a mixture of
rat liver lysosomal enzymes (tritosomes) prepared according
to the method of Trouet (1974) and two purified lysosomal
enzymes isolated from bovine spleen (Pohl et al., 1982),
cathepsin B (EC. 3.4.22.1) and cathepsin L (EC. 3.4.22.15).
The activity of the thiol-dependent proteinases in trito-
somes was determined using the substrate Bz-Phe-Val-Arg-
NAp. Release of p-nitroaniline was monitored under
standard conditions as described by gubr et al. (1986)
(AA1 cm=0.190).
Activity of cathepsin B was determined using Bz-Arg-
NAp. Enzyme (20yl of a stock solution containing
8.1 x 10-6 M active protein as determined by active site
titration using iodacetic acid (Pohl et al., 1982)) was
incubated with Bz-Arg-NAp (25 1M, 9.2 x 10-2M in DMF),
EDTA (1 mM) in citrate/phosphate buffer (935p1, pH 5.5)
and reduced glutathione (20p1, 250mM). The p-nitroaniline
liberated was determined spectrophotometrically at 410 nm,
AAI cm =0.280/10min.
Cathepsin L activity was determined using the substrate
Bz-Phe-Val-Arg-NAp. Enzyme solution (20 4ul of a
1.07mgml-1 solution as determined using A;°JO cm = 11.4,
corresponding to 4.7x 10-6M of active protein as deter-
mined by titration with 5,5'-dithiobis(2-nitrobenzoic acid),
Pagano et al., 1980), was incubated with reduced glutathione
(250 mM 20pl), citrate/phosphate buffer (940pi pH 5.5),
containing 1 mM EDTA, Bz-Phe-Val-Arg-NAp in DMF
(1.12 x 10-2 M, 20pl). The p-nitroaniline liberated was
determined spectrophotometrically at 410nm,
AA1 cm =0.830/10min
Incubation ofHPMA copolymer-drug conjugates with
lysosomal enzymes
Drug-polymer conjugates (3.8-7.2mgml 1) were incubated
at 37°C in 0.2M citrate/phosphate buffer, pH 5.5, containing
EDTA (1 mM) and reduced glutathione (5mM), with trito-
somes (0.48mlml-1, plus 0.2% Triton X-100), with
3.2
,.7
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cathepsin L (4.7 x 10-7 M) or with cathepsin B
(8.1 x 10-7 M). At various time intervals 0.1 ml of the
incubation mixture was removed and free drug (daunomycin
or puromycin) isolated by extraction into a mixture of 1 ml
of 0.2M Na2CO3/NaHCO3 buffer (pH9.8) and 1.5ml of
ethyl acetate. The organic layer was separated and the
concentration of drug determined spectrophotometrically
using the extinction coefficients given previously. Control
experiments showed the efficiency of extraction was
100+5% for daunomycin and 94.6+5% for puromycin.
Evaluation ofHPMA copolymer-drug conjugates against L1210
cells grown in vitro
L1210 cells were maintained in suspension culture (RPMI
medium plus 10% heat-inactivated horse serum, 5% CO2)
using techniques previously describedt (Zenebergh et al.,
1982). Drug testing was carried out while cells were in a
phase of exponential growth with a doubling time of 15-
20h. Cells were diluted into 1Oml of culture medium to give
a starting cell density of - 10,000 cells ml-1. They were
cultured for 24h addition of either free drug or drug
conjugate at a range of concentrations. Each was then mixed
thoroughly (including control cultures without addition)-and
cultured for 72h. Cell numbers were measured at the begin-
ning and the end of each experiment using a Coulter
counter. Cell viability was assessed microscopically using
trypan blue penetration as an indication of cell death.
In certain experiments, cells were harvested after 72h
exposure to drug or drug-conjugate and washed three times
in phosphate-buffered saline (at room temperature). The
final cell pellet was resuspended in warm (37°C) culture
medium to give a concentration of 2,000-5,000 cells per ml.
Aliquots (0.2ml) of this solution were placed in a multiwell
microtitre plate and the cells maintained at 370C/5%CO2 for
the next ten days. Daily cell samples were taken from the
microtitre plate, cell number counted and cell viability
measured as described above.
Binding and internalization of125I-labelled conjugates by
L1210 cells in vitro
Tyrosinamide residues incorporated into the HPMA
copolymers permitted polymer radioiodination using the
chloramine T method (Duncan et al., 1981). The radio-
labelled polymers produced were stable during storage and
experimentation and had a specific activity of
-25MCimg-1.
To measure binding and/or internalization of the polymer
cells were incubated at 4°C or 37°C with radiolabelled
HPMA copolymer for periods up to 72h. At each sample
time duplicate 1 ml samples of culture medium were taken,
before removing excess culture medium from the cell pellet
by washing the cells three times in PBS (room temperature).
The final cell pellet was resuspended in 1 ml PBS and, with
the two samples of culture medium, assayed for radio-
activity. Coulter counting was used to assess the cell number
present at the beginning and the end of the experiment.
Radioactivity binding to, or internalized by, the cells was
expressed as the volume of culture medium (,ul) whose
contained 'substrate was bound/captured per 106 cells (for
further definition of units see Williams et al., 1975).
Results
Release ofdaunomycin andpuromycinfrom HPMA copolymer-
conjugates during incubation with lysosomal enzymes in vitro
Release of daunomycin or puromycin from HPMA
copolymers by tritosomes or purified lysosomal enzymes,
was more effective if the drug was attached to polymer via a
Gly-Phe-Leu-Gly side-chain (Figure 2). In all cases the
extent of daunomycin and puromycin released was similar
during incubation of polymer with tritosomes or the purified
enzyme cathepsin L (at the concentration used). Cathepsin B
was however, less efficient in liberating daunomycin and
marginally less effective in releasing puromycin. In all cases,
control experiments carried out without addition of enzyme
showed no drug liberation over three days (results not
shown). The rate of drug cleavage was found to be
independent of the galactosamine content of the polymer
(results not shown).
During degradation of copolymer 10 by tritosomes to
yield free puromycin, the first cleavage position was not
between the terminal amino acid residue (glycine) and
puromycin (results not shown). Sephadex G-15 chroma-
tography of samples of incubation mixture taken at various
time intervals showed elution of a low molecular weight
puromycin derivative, either Gly-PRM or Leu-Gly-PRM.
The broader elution profile of daunomycin on Sephadex G-
15 did not permit discrimination between free drug and low
molecular weight peptidyl derivatives but HPLC analysis
indicated release of free daunomycin (results not shown).
Effect ofHPMA copolymer-drug conjugates ongrowthofL1210
and CCRFleakaemia in vitro
HPMAcopolymer-daunomycin conjugates(samples 5, 6and 8)
were all less effective than free daunomycin at inhibiting L1210
cell growth over 72h (Figure 3). It can be seen that the
inhibitoryN activity of a drug-conjugate is related to the
amino acid composition of the drug-polymer linkage, Gly-
Phe-Phe-Leu >Gly-Phe-Leu-Gly >Gly-Gly. In contrast with
these daunomycin HPMA copolymers, which did show
considerable inhibitory activity, the puromycin-containing
copolymers (samples 7, 9 and 10) were virtually inactive
against L1210 leukaemia over the concentration range
investigated (Figure 4). Free puromycin did inhibit cell
growth at these concentrations.
The effect of incorporation of the amino sugars, galacto-
samine and fucosylamine, into HPMA copolymers bearing
daunomycin is shown in Figure 5. The presence of
fucosylamine clearly enhanced the inhibitory effect of P-Gly-
Phe-Leu-Gly-DNM, whereas incorporation of galactosamine
did not. The human leukaemia, CCRF was found to be
more sensitive to HPMA-daunomycin conjugates than L1210
leukaemia, but it can be seen (Figure 6) that here
fucosylamine residues did not potentiate the activity of P-
Gly-Phe-Leu-Gly-DNM.
Evaluation ofHPMA copolymer-daunomycin conjugate
cytotoxicity against L1210 leukaemia
To determine the concentration of HPMA-conjugate con-
taining daunomycin needed to produce a cytotoxic effect,
L1210 cells were incubated with samples 8 and 12 (drug
concentrations of 16-184pgml-1) for 72h. Cells washed free
of drug conjugate were plated out at low density and their
growth curves (over 10 days) are shown in Figure 7.
Although cells incubated with the lower concentrations of
drug-conjugate did eventually show evidence of cell division,
all treated cultures grew up more slowly than untreated cell
cultures, and the cells exposed to the highest drug concen-
tration (184pgml-1) did not show any evidence of cell
division within the experimental period.
Accumulation of 125I-labelled HPMA copolymers by L1210
cells cultured in vitro
L1210 cells were incubated with 125I-labelled polymers
(samples 8, 10 and 11) for 3h, either at 37°C or 4°C. Data
shown in Figure 8(a) show the L1210 cell accumulation of
radioactivity over 3 h. It can be seen that both the
daunomycin-containing, and puromycin-containing
copolymers became associated with the cells rapidly (even at
time zero) and to a greater extent than an unsubstituted
polymer. Over a 2h incubation period there was little
progressive accumulation of radioactivity at either170 R. DUNCAN et al.
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Figure 2 Cleavage of polymer-drug conjugates by Tritosomes (a) and (d), cathepsin L, (b) and (e), and cathepsin B (c) and (f).
Release of drug from the peptidyl side-chains GlyPheLeuGly-drug (0 0) and GlyPhePheLeu-drug (0 O) is shown. For
daunomycin-containing polymers, (0 O) represents sample 6 and ( 0) sample 8. For puromycin (0 O) sample 7
and ( *) sample 10. The incubation conditions are described in the Methods. The results shown are typical data,
representative of at least two experiments in each case.
temperature. Further experiments showed that incorporation
of both daunomycin and fucosylamine into HPMA
copolymer structure greatly increased the cell association of
copolymer. This was also apparently not followed by
progressive accumulation of radioactivity by the cells over
3h.
Discussion
N-(2-Hydroxypropyl)methacrylamide copolymer-drug con-
jugates have been synthesized to contain little or no free
drug (less than 0.1% relative to the drug bound). The
solubility of daunomycin-containing copolymers in physio-
logical buffers was limited, particularly above a conjugate
concentration of 25 mgml-', and this seemed to be a
temperature-dependent phenomenon. Increasing temperature
(from 20 to 30°C) sometimes caused precipitation. This
process was found to be reversible (by lowering the tem-
perature) and was probably due to formation of aggregates
of polymer chains. These polymer-polymer (or polymer-
protein) interactions are currently being investigated further
(Ulbrich et al., 1986). Problems of solubility were not
observed during incubation of puromycin-containing
polymers.
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Figure 3 Effect of oligopeptide spacer on the toxicity of
polymer-daunomycin to L1210 cells cultured in vitro. Cells were
cultured for 72h in the presence of free daunomycin ([ Cl)
or polymer-drug conjugates; polymer 5 (0 0) polymer 8
(0 O), polymer 6 (-U*). The points represent the mean
(±s.e.) of at least three experimental values.
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Figure 5 Effect of incorporation of carbohydrate residues on
the toxicity of polymer-daunomycin conjugates against L1210
cells cultured in vitro. Cells were incubated for 72h with free
daunomycin ( 0) or polymer-drug conjugates; polymer 8
(-----), polymer 11 (A A), polymer 12 (- E).
Points represent the mean (+s.e.) of at least three experimental
values.
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Figure 4 Toxicity of polymer-puromycin against L1210 cells
cultured in vitro cells were cultured for 72h in the presence of
free puromycin (0 *) or polymer-drug conjugates; polymer
7 (0 0), polymer 10 (0 O), polymer 9 (- *).
Greatest enzymatic release of drug (both daunomycin and
puromycin) occurred when the peptide side-chain Gly-Phe-
Leu-Gly was used as a polymer-drug spacer. Comparing the
rate of drug release with that previously reported for
liberation of terminal p-nitroaniline (NAp) residues from
HPMA copolymers (Duncan et al., 1983) shows that, for the
same oligopeptide side-chain, the rate of cleavage was
puromycin >NAp>daunomycin. This must reflect the
specificities of the substrate-enzyme active site interactions,
as discussed in detail by Kopecek (1984). It was also found
(results not shown) that HPMA copolymer-drug conjugates
bearing both daunomycin and carbohydrate residues (e.g.
polymer 11) were cleaved at identical rates to those without
sugar moieties, indicating that neighbouring carbohydrate
0 10 20 30 40
Daunomycin concentration (,ug ml-')
50
Figure 6 Effect of polymer-daunomycin conjugates on the
growth of CCRF cells in vitro. Cells were incubated for 72h in
the presence of free daunomycin (0), or polymer conjugates;
polymer 8 (0 O) and polymer 12 ( 0). Each point
represents the mean (±s.e.) of at least three experimental values.
residues did not effect enzyme access or specificity. Trouet
et al. (1982) have also shown that biodegradable peptidyl
spacers may be used as drug-carrier linkages. They bound
daunomycin to succinylated bovine serum albumin via amino
acids (di-, tri- and tetra-peptides), and showed that the
sequence Ala-Leu-Ala-Leu-DNM released 75% of the bound
drug during a 10h incubation with tritosomes. They also
found the efficiency of drug release from albumin was
directly related to the length of the oligopeptide spacer, an
observation we have reported previously in relation to the
hydrolysis of side-chains in HPMA copolymers (Kopecek et
al., 1981). However, degradation of HPMA copolymer side-
chains is a complex process and is influenced by length, side-
chain composition and terminal group.
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Figure 7 Colony forming ability of L1210 cells after previous exposure (72h) to polymer-daunomycin conjugates. Cells were
incubated in culture medium without addition (0 0) or in the presence of HPMA-daunomycin; sample 12, 0.25mgml-1
(0 O), sample 8, 0.5mgml-1 (A A), sample 12, 0.5mgml-' (m *) and samples 8 and 12 at a polymer-drug
concentration of 2mgml-' (A A). The polymer-drug concentrations given above represent daunomycin concentrations of
184jigml for sample 8 (2mgml-1) and 130figml
- for sample 12 (2mgml-1). Note that these cell cultures reach a maximum
tolerated cell density (-.8 x IO') above which the culture degenerates.
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Figure 8 Cell association of 1 21-labelled HPMA copolymer-drug conjugates incubated in vitro with L1210 cells. (a) Radiolabelled
copolymer, samples 8, 10 and II and an unsubstituted control polymer (all at 250pgml-1) were incubated with L1210 cells for
0 min, or 3 h at 4 C' V/7 or 37 C _ Cell association with radioactivity at the end of the incubation period is
shown, mean +s.e. in terms of lil of culture ImlediuI whose contained substrate becomes associated with 106 cells. (b) Cell
association of polymer-daunomycini conjugates (37 C) containing; no other substitutent sample 8, galactosamine _
sample 11, or fucosylamine sample 12, are compared. The mean cell association (+s.e.) is shown.
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For many years it has been postulated that the anthra-
cycline antibiotics, daunomycin and adriamycin, interfere
with cell division by intercalating into the DNA double-helix
and therefore prevent normal mitosis. However, more
recently it has become apparent that the anthracyclines can
also interact with the cell membranes and induce detrimental
effects from the outside of the cell (Tritton & Yee, 1982;
Tokes et al., 1982). In this study free daunomycin was shown
to be very effective at inhibiting L1210 cell growth (Figure
3). Polymer-daunomycin conjugates were also able to
prevent growth, in a dose-dependent manner (Figure 3) and
this effectiveness varied with the oligopeptide spacer chosen
to join polymer and drug. In this study the relative order
of activity of drug conjugates against L1210 cells was P-
Gly-Phe-Phe-Leu-DNM >P-Gly-Phe-Leu-Gly-DNM >P-Gly-
Gly-DNM. Previously we have shown, using P-Gly-
Gly[3H]DNM, that the glycylglycyl spacer is not degradable
by lysosomal enzymes (Kopecek & Duncan, 1986) and this
may account for its limited activity. Cell-surface activity of
this conjugate would explain the growth-inhibiting activity
observed. Both drug-conjugates containing oligopeptide
sequences known to be degradable by lysosomal enzymes
(Figure 2) were found to be more effective, but it is perhaps
surprising that polymer 6 displayed greater activity than
polymer 8, as the former gave a slower rate of daunomycin
release on incubation with rat and bovine lysosomal enzymes
(Figure 2). This apparent discrepancy could represent a
difference between the L1210 lysosomal enzymes and the
other lysosomal enzymes studied, or alternatively may
indicate increased daunomycin-membrane interactions due to
the hydrophobic sequence Phe-Phe-Leu of polymer 6 side-
chains. The latter could increase membrane-induced toxicity.
Data shown in Figure 8 confirm that all the radioiodinated
HPMA copolymers investigated containing daunomycin have
a much greater affinity for L1210 cells than similar polymers
without this drug. It is important to note that several
different preparations of HPMA-daunomycin were used
(samples 5, 8 and 12) and they showed reproducible, dose-
dependent toxicity.
In contrast, the puromycin-containing conjugates were
much less active against L1210. Since free puromycin did
inhibit growth over the same time-period, it must be
concluded that the L1210 cells were unable to release
puromycin from the drug-conjugate (as the rat and other
lysosomal enzymes did; Figure 2), that puromycin was
released intracellularly in an inactive form or the cells did
not accumulate the macromolecular drug quickly enough to
ensure the required intracellular concentration.
Cell-surface receptors that recognize carbohydrate residues
on macromolecules can, in theory, be used to promote more
rapid cellular uptake of drug-conjugates (Duncan, 1986).
Utilization of the known receptor on L1210 cell membranes
recognizing fucose residues (Monsigny et al., 1984) enabled
the design of the HPMA copolymer-daunomycin conjugate
(polymer 12) with increased activity against the mouse
leukaemia in vitro (Figure 5). A similar drug-conjugate
containing galactosamine (substituted at approximately the
same mol%) did not differ significantly in activity from the
non-carbohydrate-containing, polymer 11. This observation
demonstrates the possibility of increasing the therapeutic
index of a macromolecular drug-carrier by increasing the
rate of capture by particular target cells. However, obser-
vation that the human T-cell lymphoblastoid leukaemia
CCRF did not show the same specificity regarding the
fucose-containing polymer (Figure 6) illustrates the difficulty
in extrapolating any potentially useful targeting system from
one cell type or another. It is interesting to note that the
human leukaemia was more sensitive to both free and
polymer-bound daunomycin than L1210, and indeed the
maximum growth-inhibiting effects for CCRF (shown in
Figure 6) were greater than those found for any polymer-
drug conjugate against L1210 cells.
Investigations into the mechanism of action of HPMA-
drug conjugates are continuing. At this stage we can
confirm, using the analysis reported earlier, HPLC analysis
of the preparations, and the measured activities of dauno-
mycin-HPMA conjugates against L1210 and CCRF cells in
vitro are not due to the presence of free drug in the
conjugate. This contrasts with observations of Van Heeswijk
et al., (1984), who prepared polyglutamic acid-adriamycin
conjugates, tested using an L1210 clonogenic assay and
reported cytotoxic activity. Since these conjugates contained
0.5-2% weight free adriamycin, their cytotoxicity was largely
ascribed to free adriamycin.
In all cases maximum inhibition of cell growth by
polymer-drug was between 10-20% (Figures 3-5) and this
can be explained by the nature of assay. Measurement of
radiotracer incorporation (e.g. [3H]thymidine) would be
expected to register zero in respect of a control valve over
the same incubation periods. To determine whether anti-
cancer agents are lethal to tumour cells or simply cause a
transient retardation of cell division it is important to
perform clonogenic assays (Roper & Drewinko, 1976). Con-
centrations of daunomycin conjugate can be employed that
are efficiently cytotoxic: no cell regeneration was observed
over the 10 days subsequent to exposure of L1210 cells to
the highest concentrations of polymers 8 and 12. The ability
of daunomycin-HPMA copolymer conjugates to destroy
L1210 cells has recently been demonstrated in vivo (Duncan
et al., 1986). HPMA-daunomycin conjugates administered
intraperitoneally to DBA2 mice (daunomycin concentration
5mgkg-') prolong the survival time (and in the cases of
optimum treatment produce long-term survivors (>50
days)), of individuals previously inoculated intraperitoneally
with 105 L1210 cells.
This study shows that polymer-drug conjugates can be
synthesized that display many of the necessary features that
could allow controlled delivery of anticancer agents in vivo.
The conjugates contain little or no free drug; drug is only
liberated by specific enzymatic hydrolysis; conjugates display
cytotoxic activity against mouse and human leukaemia in
vitro; activity is related to the sequence of the oligopeptide
spacer used to attach drug to polymer; and activity can be
potentiated by incorporation of residues (such as fuco-
sylamine) into the polymer structure that target to specific
cell-membrane receptors. Further experiments are in progress
to characterize the pharmacokinetics of these conjugates in
vitro and determine their therapeutic index against model
tumours in vivo.
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